These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36837481)

  • 1. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
    [No Abstract]   [Full Text] [Related]  

  • 2. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI; Park H; Park S; Shin JY; Kim YH
    BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 5. Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study.
    Zhai L; Wang Z; Yu W
    Ther Adv Respir Dis; 2024; 18():17534666241276800. PubMed ID: 39235441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and predictors of progression in progressive pulmonary fibrosis.
    Cen Z; Cen T; Ding Q; Zhang Y; Tang P; Lv C; Wu T
    Ann Med; 2024 Dec; 56(1):2406439. PubMed ID: 39310989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.
    Løkke A; Castello L; Pinheiro Martins P; Soulard S; Hilberg O
    Adv Ther; 2023 Dec; 40(12):5502-5518. PubMed ID: 37837527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
    Pugashetti JV; Adegunsoye A; Wu Z; Lee CT; Srikrishnan A; Ghodrati S; Vo V; Renzoni EA; Wells AU; Garcia CK; Chua F; Newton CA; Molyneaux PL; Oldham JM
    Am J Respir Crit Care Med; 2023 Jan; 207(1):69-76. PubMed ID: 35943866
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.
    Huang H; Wang Q; Xu Z
    Ther Adv Respir Dis; 2024; 18():17534666241288417. PubMed ID: 39415340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
    Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C; Cottin V
    Curr Opin Pulm Med; 2022 Sep; 28(5):407-413. PubMed ID: 35938201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.
    Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease: A Multicenter Study.
    Khor YH; Farooqi M; Hambly N; Johannson KA; Marcoux V; Fisher JH; Assayag D; Manganas H; Khalil N; Kolb M; Ryerson CJ;
    Chest; 2023 Feb; 163(2):345-357. PubMed ID: 36089070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial Lung Disease and Progressive Pulmonary Fibrosis: a World Trade Center Cohort 20-Year Longitudinal Study.
    Cleven KL; Zeig-Owens R; Mueller AK; Vaeth B; Hall CB; Choi J; Goldfarb DG; Schecter DE; Weiden MD; Nolan A; Salzman SH; Jaber N; Cohen HW; Prezant DJ
    Lung; 2024 Jun; 202(3):257-267. PubMed ID: 38713420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease.
    Sakamoto S; Suzuki A; Homma S; Usui Y; Shimizu H; Sekiya M; Miyoshi S; Nakamura Y; Urabe N; Isshiki T; Kurosaki A; Kishi K
    Sci Rep; 2023 Oct; 13(1):17616. PubMed ID: 37848575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study.
    Jang JH; Choe EJ; Jung SY; Ko J; Kim DW; Lee JH
    Medicine (Baltimore); 2024 May; 103(20):e38226. PubMed ID: 38758869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.